Alembic Pharma Expands US Focus on Branded Prescription Medications

Alembic Pharmaceuticals Expands Branded Specialty Drugs Portfolio in the US

Alembic Pharmaceuticals Ltd is diversifying its business by expanding its branded specialty drugs portfolio in the US, a strategic move to counter the ongoing generic pricing pressure in the market. As part of its 'twin engine play', the company aims to boost growth in the US market, where the generics market has been facing continued pricing pressure from customer consolidation.

The company entered the branded specialty drugs segment in the fourth quarter of 2025-26, launching Pivya in March to treat uncomplicated urinary tract infections in women. The entry into branded drugs marks a significant shift for the generics drugmaker, which will now focus on building a franchise around its branded products. The company plans to strengthen its women's health segment before expanding into other therapeutic areas.

The generics market has been facing significant pricing pressure, leading to reduced margins for companies. According to G. Krishnan, Chief Financial Officer, the pricing pressure is here to stay, and the only way to respond is to be more innovative with processes and cost controls in the core business. While the company hopes to push into branded specialty drugs, which offer a better value proposition in the US, its core generics business will continue to remain a priority.

Read also: Oshea Herbals Aims for Rs 650 Crore Revenue Amidst Expansion Efforts

In 2024-25, the company acquired US-based Utility Therapeutics for $12 million, gaining exclusive commercial rights to Pivya (pivmecillinam) and another antibiotic, mecillinam. Following the acquisition, the company worked on building a field force and a launch plan for the product, which was soft-launched in February. The company is now present in almost 30 territories and expects to see growth and scale in volumes over the next three to four quarters.

US Business Growth

The US business accounts for 30% of Alembic Pharmaceuticals' total revenue. The company expects low double-digit to mid-teens growth in the US in 2026-27 as it scales up its branded business. In Q4 FY26, revenue from operations increased by 4% on a year-on-year basis to ₹1,848 crore, while net profit grew 29% to ₹203 crore.

Read also: Suzlon to Expand Business Scope Beyond Wind Energy, Invests Rs 500 Crore in New Subsidiary This Fiscal Year